

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 January 2025 (16.01.2025)



(10) International Publication Number
WO 2025/014827 A1

(51) International Patent Classification:

A61K 31/535 (2006.01) A61K 31/437 (2006.01)
A61K 31/573 (2006.01) A61K 31/519 (2006.01)
A61P 35/00 (2006.01) C07D 475/08 (2006.01)

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(21) International Application Number:

PCT/US2024/036942

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

05 July 2024 (05.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/525,585 07 July 2023 (07.07.2023) US

(71) Applicant: ACROTECH BIOPHARMA INC. [US/US];
279 Princeton Hightstown Road, East Windsor, New Jersey
08520 (US).

(72) Inventor: ANVEKAR, Ashish; c/o AcrotechBiopharma
Inc., 279 Princeton Hightstown Road, NEW YORK, New
Jersey 08520 (US).

(74) Agent: GONCHER, Scott; ONE VANDERBILT, C/O
GREENBERG tRAURIG, LLP, NEW YORK, New York
10017 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: PRALATREXATE AND COP COMBINATION FOR THE TREATMENT OF PATIENTS WITH PERIPHERAL T CELL LYMPHOMA

(57) Abstract: Methods for treating peripheral T-cell lymphoma include administering to a subject a combination of Cyclophosphamide, Vincristine, Prednisone, and Pralatrexate, wherein the combination does not include doxorubicin. The treatment may be administered in repeated three-week cycles, optionally including a drug holiday.

WO 2025/014827 A1